|
Response Category, n (%)
|
Eribulin/S-1 (n = 30)
|
|---|
|
Objective Response Rate; 95%CI
|
10 (33.3); 17.3–52.8
|
|
Complete Response
|
1 (3.3)
|
|
Partial Response
|
9 (30)
|
|
Stable Disease
|
12 (40)
|
|
Progressive Disease
|
7 (23.3)
|
|
Clinical Benefit Rate; 95%CI
|
13 (43.3); 25.5–62.6
|
|
Disease Control Rate; 95%CI
|
22 (73.3); 54.1–87.7
|
- The ORR was 33.3% (95% CI: 17.3 to 52.8), the DCR was 73.3% (n = 22; 95% CI: 54.1 to 87.7), and the CBR was 43.3% (n = 13; 95% CI: 25.5–62.6)
- In this study, ORR was evaluated only among patients who had measurable baseline disease according to the Response Evaluation Criteria in Solid Tumours, version 1.1
- Abbreviations: ORR Overall response, CBR Clinical benefit rate: CR + PR + SD (> 6 months); DCR Disease control rate: CR + PR + SD
